United Therapeutics (Nasdaq: UTHR) reported Q2 2026 revenue of $783.3 million, down 2% from $798.6 million a year earlier, while diluted EPS rose 13% to $7.27 from $6.41 for the quarter ended June 30. Net income increased 8% to $333.0 million even as operating income fell 9%, with a sharply lower effective tax rate and fewer diluted shares driving the divergence.

Core financial results

Revenue pressure centered on the Tyvaso franchise, where growth in Tyvaso DPI was insufficient to offset lower Nebulized Tyvaso sales. At the same time, higher cost of sales and R&D spending pushed operating expenses above the prior-year level.

The resulting decline in operating profit contrasted with higher net income and EPS, making the composition of earnings more important than the headline bottom-line growth.

Gross profit and margins are calculated from the reported revenue and expense figures and are approximate because of rounding.

Product and geographic performance

Tyvaso remained the largest franchise at approximately 58% of quarterly revenue. Its performance was mixed: Tyvaso DPI continued to grow, but the larger decline in Nebulized Tyvaso left total Tyvaso revenue below the prior-year level.

Unituxin recorded the fastest percentage growth among the major products, while Remodulin also declined. The following table shows the main product-level movements.

Tyvaso DPI benefited from higher sales quantities and pricing, partly offset by higher gross-to-net deductions. Nebulized Tyvaso was hurt primarily by a $37.6 million decline associated with lower U.S. quantities sold, while Remodulin’s lower U.S. volume was partly offset by international growth. Management said competitive therapies negatively affected Nebulized Tyvaso, Tyvaso DPI, and Remodulin sales.

Geographically, U.S. revenue declined by approximately 3% to $733.6 million. Rest-of-world revenue rose by approximately 28% to $49.7 million, but remained too small to offset domestic weakness.

Profitability, balance sheet and capital allocation

Total cost of sales increased 14% to $99.5 million despite the revenue decline. The increase was primarily attributed to inventory reserve expense, including $7.5 million of estimated losses under a commercial supply agreement intended to maintain sufficient Tyvaso DPI inventory.

R&D expense rose 9% to $146.3 million, reflecting increased spending on cardiopulmonary treatment projects and a higher fair value for contingent consideration tied to acquired manufactured-organ and organ-alternative projects. SG&A declined 3% to $206.7 million, but this comparison benefited from a $21.7 million property impairment recorded in 2025 that did not recur. Excluding that item, general and administrative costs increased with headcount and consulting expenses, while sales and marketing expense rose 20%.

United Therapeutics ended the quarter with $3.80 billion in cash, cash equivalents, and marketable investments, compared with total liabilities of $819.8 million. In March, the company entered accelerated share repurchase agreements covering approximately $1.5 billion of common stock. After the final settlement in August, total shares repurchased under those agreements reached approximately 2.76 million, while $500 million remained available under the broader authorization.

Funding the repurchases affected financial income: interest income fell to $31.5 million from $51.3 million because marketable securities were sold to finance the accelerated repurchases.

Lower taxes and fewer shares offset weaker operating earnings

The principal reason net income increased while operating income declined was the lower tax burden. Pretax income fell to $372.7 million from $408.4 million, but income tax expense dropped to $39.7 million from $98.9 million. The effective tax rate declined to 11% from 24%, primarily because of increased excess tax benefits from share-based compensation.

Other income was not a major offset at the aggregate level: total other income, net, slipped to $41.9 million from $43.9 million as lower interest income outweighed improved gains on equity securities. Meanwhile, the weighted-average diluted share count decreased to 45.8 million from 48.3 million, allowing EPS to grow faster than net income.

Management view and pipeline

Management emphasized recent regulatory submissions for ralinepag tablets in pulmonary arterial hypertension and Nebulized Tyvaso in idiopathic pulmonary fibrosis. It also plans to file an investigational new drug application for ralinepag DPI and an application for treprostinil SMI later in 2026. Management views potential approvals for the first two programs by next year as important growth opportunities, although they remain subject to regulatory review.

Operationally, President and COO Michael Benkowitz said Tyvaso DPI exited the quarter at record levels for starts, referrals, commercial patients, and total patients. No numerical patient metrics were provided, and the reported revenue growth remained limited to 4% amid competitive pressure and higher gross-to-net deductions.

The company is also advancing clinical work involving manufactured liver, kidney, heart, and lung products and plans to launch two xeno-organ production facilities in Minnesota and Texas later in 2026.

Recent insider transactions

The six-month insider summary reports 1,578,699 shares purchased across 164 transactions and 1,424,233 shares sold across 161 transactions, producing net purchases of 154,466 shares. Total reported insider holdings were approximately 870,160 shares.

The latest 10 supplied records all involved CEO Martine A. Rothblatt and were classified as indirect transactions. They consisted of paired derivative-security exercises or conversions and subsequent sales rather than explicit open-market purchases.

Risks investors should monitor

• Competitive pressure: Management said competing therapies negatively affected Tyvaso DPI, Nebulized Tyvaso, and Remodulin. Continued pressure could constrain volumes across the company’s largest products.
• Tyvaso concentration and product mix: Total Tyvaso generated approximately 58% of revenue, and DPI growth did not offset the decline in the nebulized product during the quarter.
• Operating margin pressure: Higher inventory reserve costs and continued R&D investment contributed to lower gross and operating margins despite the reported increase in net income.
• Dependence on tax benefits for earnings growth: The increase in net income relied heavily on an effective tax rate of 11%, compared with 24% a year earlier. A less favorable tax benefit would reduce this cushion against weaker operating profit.
• Pipeline execution: Management’s growth expectations depend partly on successful regulatory reviews and development of pulmonary disease treatments and manufactured-organ programs.

Summary

United Therapeutics’ Q2 2026 results showed weaker revenue and operating profitability as Nebulized Tyvaso declined and costs increased. A lower tax rate and reduced share count nevertheless lifted net income and EPS. The main issues to monitor are whether Tyvaso DPI demand can translate into faster reported sales, whether competitive pressure on established products persists, and whether the company’s pulmonary disease pipeline advances through regulatory review.

Find out more